Top Page
Akeso, Inc.
(9926)
Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)
Akeso, Inc. Business Overview & Revenue Model
Akeso, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.51B | 2.12B | 4.53B | 837.66M | 225.63M | 0.00 |
| Gross Profit | 2.02B | 1.83B | 4.39B | 734.54M | 195.41M | -1.90M |
| EBITDA | -704.02M | -604.99M | 2.17B | -1.27B | -1.32B | -1.01B |
| Net Income | -846.01M | -514.51M | 2.03B | -1.17B | -1.07B | -1.04B |
Balance Sheet | ||||||
| Total Assets | 13.29B | 12.75B | 9.18B | 5.50B | 4.81B | 3.86B |
| Cash, Cash Equivalents and Short-Term Investments | 7.14B | 7.32B | 4.88B | 2.29B | 2.65B | 2.80B |
| Total Debt | 4.54B | 3.95B | 2.99B | 1.88B | 859.42M | 198.99M |
| Total Liabilities | 6.93B | 6.00B | 4.66B | 2.95B | 1.53B | 405.73M |
| Stockholders Equity | 6.44B | 6.81B | 4.69B | 2.64B | 3.16B | 3.19B |
Cash Flow | ||||||
| Free Cash Flow | -163.83M | -1.11B | 1.59B | -2.02B | -1.71B | -1.06B |
| Operating Cash Flow | -408.62M | -527.62M | 2.47B | -1.24B | -1.00B | -617.77M |
| Investing Cash Flow | -3.48B | -1.52B | -4.00B | -889.75M | -579.59M | -555.70M |
| Financing Cash Flow | 2.84B | 3.39B | 960.89M | 1.49B | 1.59B | 2.88B |
Akeso, Inc. Technical Analysis
Akeso, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $146.17B | 32.26 | 9.79% | ― | 16.90% | 63.11% | |
| ― | $147.53B | 115.91 | 8.41% | ― | 52.78% | ― | |
| ― | $124.48B | 31.18 | 11.72% | 1.27% | 13.69% | 50.71% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$106.12B | -113.16 | -14.40% | ― | 33.46% | -7.60% | |
| ― | HK$38.08B | -21.94 | -15.06% | ― | 39.02% | 48.26% | |
| ― | HK$52.13B | -37.14 | -45.12% | ― | 47.62% | 28.72% |
Akeso, Inc. Corporate Events
Akeso, Inc. announced the results of its HARMONi-6 trial, which were presented at the 2025 European Society For Medical Oncology Symposium and published in The Lancet. The trial demonstrated that ivonescimab plus chemotherapy significantly improved progression-free survival in patients with advanced sq-NSCLC compared to tislelizumab plus chemotherapy. The trial results highlight the superior efficacy and safety profile of ivonescimab, reinforcing Akeso’s leadership in oncology and addressing clinical gaps in current treatments.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$131.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. has successfully completed the placing of new and existing shares, raising approximately HK$3,493.01 million in net proceeds. The funds will primarily be used for global and China R&D of its innovative pipeline, including clinical trials for cancer treatments and the development of next-generation therapeutic technology platforms.
The most recent analyst rating on (HK:9926) stock is a Buy with a HK$177.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. has announced the placement of new and existing shares under a general mandate. The company has entered into an agreement with a placing agent to place 23,550,000 shares at a price of HK$149.54 per share. These shares will be offered to professional, institutional, or other independent investors, ensuring that no single investor becomes a substantial shareholder. This move is expected to enhance Akeso’s financial flexibility and strengthen its market position.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. reported a 37.75% increase in revenue for the first half of 2025, reaching RMB1,411.5 million, driven by a 49.20% rise in commercial sales. Despite the revenue growth, the company experienced a loss of RMB588.3 million, attributed to increased equity investment losses in Summit Therapeutics, higher R&D expenses, and elevated equity incentive costs.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. has outlined the terms of reference for its Nomination Committee, which was established by the board of directors in April 2020. The committee’s primary role is to identify and recommend suitable candidates for the company’s board of directors and to develop nomination guidelines in compliance with relevant laws and regulations. The committee is composed mainly of independent non-executive directors and is required to meet at least once a year, with provisions for additional meetings as needed. This structure aims to ensure effective governance and strategic leadership within the company.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$158.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. This meeting is crucial as it will determine the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market position.
The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.